Retatrutide 30 mg
Retatrutide 30 mg is a research-grade peptide that is studied for weight loss, supplied in Australia by Australian Research Peptides (ARP). Every batch is HPLC-tested and this strength's certificate is published. This 30 mg vial is in stock now and dispatched same business day when ordered before 12pm AEST, to all states and territories. For in vitro research purposes only.
Metabolic Research · Lyophilised Powder · Batch-tested · SKU ARP-RET-30
$319.99
2+ vials: 5% off — applied automatically in the cart
Presentation
30 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Metabolic Research
Same-day dispatch on business-day orders placed before 12pm AEST, Mon–Fri
Tracked shipping Australia-wide · typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, or dosing information is provided.
Frequently Bought Together
About Retatrutide 30 mg
The phase 3 obesity trial reported average body weight down 25.0% against 3.9% on placebo, with three receptors engaged at once rather than one or two. This is the 30 mg Retatrutide vial, the largest of three, listed as ARP-RET-30.
The 30 mg certificate records 99.482% — measured on this lot, never carried across from the 10 mg and 20 mg vials.
In vitro obesity and weight loss research purposes only. Australian Research Peptides does not supply Retatrutide for human or veterinary use.
Retatrutide 30 mg specifications, storage and shipping
- Compound: Retatrutide
- Quantity: 30 mg
- SKU: ARP-RET-30
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed on every batch to a minimum of 99% purity — the measured result for your batch is stated on its Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Batch traceability: every batch is tested, with its certificate published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Every batch undergoes HPLC purity analysis and mass-spectrometry identity confirmation. The full laboratory report is published in the COA library.
Business-day orders before 12pm AEST are dispatched the same day with tracked, discreet shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about Retatrutide 30 mg
This Retatrutide 30 mg question guide from Australian Research Peptides is specific to the exact listing, with live buying details, size comparisons, concentration calculations, storage, testing and the inherited product background grouped separately. Start with the quick answers or jump to the topic you need.
Exact strength, quantity and listing fit
Three 10 mg Retatrutide vials cost $398.97; one 30 mg vial is $319.99 — $78.98 less, and two fewer vials to store.
Per milligram, Retatrutide 30 mg works out to about $10.67 — $319.99 across 30 mg. The 10 mg Retatrutide vial works out to about $14.00 a milligram.
Thirty milligrams of freeze-dried retatrutide, the largest listing Australian Research Peptides holds for this compound and three times the entry vial. Everything three small vials contain arrives under a single seal instead.
At three millilitres this vial carries thirty 0.1 mL portions of one milligram, or fifteen 0.2 mL portions of two milligrams. Every portion is triple the mass the entry vial gives at that same make-up volume.
Fixed costs per vial — glass, seal, label, packing, freight — do not rise with the powder inside, so spreading them across thirty milligrams lowers the rate. All three listings show their own figure, so the gap reads directly.
Extended or multi-arm work, where one seal covering the whole run matters more than keeping unopened vials in reserve. Once made up, the solution carries one storage history rather than three.
Live price, stock and Australian buying
Australian Research Peptides (ARP) sells Retatrutide 30 mg in Australia under ARP-RET-30, at $319.99. Standard tracked post and Express Post carry Retatrutide 30 mg to all states and territories.
Retatrutide 30 mg is $319.99 a vial (ARP-RET-30). Two 30 mg vials come to $607.98 after Retatrutide's 5% multi-vial discount, $32.00 off.
Yes, on both services. One Retatrutide 30 mg vial at $319.99 passes $199 for free Standard tracked post, and $299 for free Express Post, with nothing else in the basket.
$319.99 delivered in Australia. Retatrutide 30 mg is $319.99, over both free-post marks, so ARP-RET-30 by Standard tracked post or Express Post is still $319.99.
One. A single 30 mg Retatrutide vial is $319.99, already past $299, so free Express Post needs no second 30 mg vial beside ARP-RET-30.
Retatrutide comes from Australian Research Peptides, not from Chemist Warehouse: it holds no Australian registration, so no pharmacy chain here can stock it, dispense it or write a script against it, and there is no approved pen or pre-filled device version in this country. ARP lists it as a research compound — freeze-dried powder in a sealed vial, supplied for in vitro research purposes only.
Reconstitution and concentration calculations
Reconstituted retatrutide keeps at 2 to 8 °C for eight to twelve weeks. That is the storage condition Australian Research Peptides publishes for every HPLC Verified line it sells. Keep the solution dark, and never refreeze one that has thawed. For holds longer than that, Bachem and GenScript both advise splitting it into single-use aliquots and freezing them below -15 °C.
Retatrutide at 30 mg/mL needs 1 mL; Retatrutide at 15 mg/mL needs 2 mL. ARP-RET-30 is 30 mg dry: water sets ARP-RET-30 strength, never its mass.
Three millilitres of bacteriostatic water gives 10 mg/mL, two millilitres gives 15 mg/mL, one millilitre gives 30 mg/mL. Reaching the 5 mg/mL that suits the smallest listing would take six millilitres.
Exactly, with nothing left over: three millilitres empties a small diluent vial and takes this listing to 10 mg/mL. Anything weaker needs the larger water vial, or a second small one.
Product identity and research background
Retatrutide is a synthetic peptide of 39 amino acids, developed by Eli Lilly under the code LY3437943 and studied in obesity and type 2 diabetes research. It reaches the GIP, GLP-1 and glucagon receptors together, where single- and dual-receptor designs are the norm. The chain is one engineered molecule rather than a mixture of separate peptides, built on a GIP backbone with a twenty-carbon fatty di-acid bonded onto it. That fatty group is the part that makes it long-acting.
Retatrutide switches on three different receptors at the same time. In laboratory assays gathered by Goldney's 2025 review, it is 8.9 times more potent at the GIP receptor than human GIP itself. It is 2.5 times less potent than GLP-1 at the GLP-1 receptor, and 2.9 times less potent than glucagon at the glucagon receptor. That same review puts the measured half-life at roughly six days, stretched by the C20 fatty di-acid binding albumin.
Retatrutide has run through phase 1, phase 2 and phase 3 trials in obesity and type 2 diabetes. Jastreboff 2023, in the New England Journal of Medicine, ran the phase 2 obesity trial over 48 weeks in 338 adults. Average body weight fell 24.2% on the 12 mg weekly dose against 2.1% on placebo. Phase 3 TRIUMPH-1 ran 80 weeks in 2,339 adults and reported 25.0% against 3.9% on placebo. The material described in those trials is not the material sold on this page.
A retatrutide vial holds one substance and nothing else. No carrier, no second peptide, no liquid. It is a freeze-dried solid, white to off-white, behind a tamper-evident seal. The C20 fatty di-acid is chemically bonded into the peptide chain rather than added alongside it, which is why the dry contents count as a single compound. The milligram figure on the listing is peptide weight.
Retatrutide clears slowly, with Goldney's 2025 review reporting a mean half-life close to six days. A week-long persistence means concentrations build across the first month of repeated administration before levelling off. That number describes one thing only: how long the molecule stays measurable in blood. The obesity trials read their results at 48 and 80 weeks instead, and rival listings routinely offer the first figure as though it answered the second.
Retatrutide has 39 amino acids in one continuous synthetic chain. It is a single engineered molecule, not a blend of separate peptides mixed together. The chain is built from a GIP peptide backbone with a C20 fatty di-acid attached to it. No residue-by-residue sequence appeared in the public records checked. The milligram figure on the vial is weight, not a residue count.
Retatrutide's published trial dosed weekly for 48 weeks and escalated gradually, with the largest weight changes accumulating over the full period rather than in the first weeks. Blood-glucose effects appeared earlier than weight changes. The trial ran no shorter arm, so there is no published answer for what happens in two or four weeks — that figure simply was not measured.
Retatrutide's reported side effects in its phase 2 obesity trial were mostly gastrointestinal — nausea, diarrhoea, vomiting and constipation — and they rose with dose, which is why the trial escalated slowly rather than starting high. They were graded mild to moderate. This is trial data in supervised participants, not a safety profile for unsupervised use, and no regulator has reviewed it.
Storage, condition and testing
Yes — Retatrutide is freeze-dried, and ten milligrams of dried peptide occupies almost no space: commonly a thin white disc, or a faint film on the glass base that overhead lighting washes out entirely. Tilting the container slowly against a dark surface usually reveals it. The 20 mg and 30 mg strengths carry two and three times that solid, so they read as an obvious cake. Weight rather than visible bulk is what batch analysis records.
Retatrutide should be kept sealed, cold and dry, away from moisture. The freeze-dried powder pulls water out of the air, so let a cold vial reach room temperature before you break the seal. Bachem's peptide handling guidance puts lyophilised material below -15 C for long-term storage and 4 C for short periods. Colder is better, and that guidance prefers -50 C or lower for long holdings.
Trapped air explains almost every cloudy Retatrutide vial. Directing the stream onto the cake, or shaking rather than swirling, whips microbubbles through the liquid and they scatter light exactly as turbidity does, then rise and disperse within a few minutes at rest. Cold glass slows dissolution as well. Haze still present after ten minutes at room temperature points instead to undissolved solid or aggregation, and the 30 mg strength takes longest because it holds three times the material.
Every Retatrutide batch Australian Research Peptides supplies goes through two separate analyses before it is sold, one measuring purity and the other confirming identity. HPLC produces the purity figure. Mass spectrometry then establishes that the molecule really is retatrutide and not something that presents identically as a dry powder. Identity is the one that matters here, because a shortened chain or a stripped fatty group still looks like white powder.
Delivery, payment and access questions
Australian Research Peptides Pty Ltd, trading as ARP, is the supplier of retatrutide in Australia, an Australian company dispatching from Sydney. The compound is catalogued under Metabolic Research by its development code LY3437943. Every batch is HPLC-tested. PayID and bank transfer are the only two routes accepted — no cards, wallets or crypto.
Retatrutide is not approved for therapeutic use by the TGA, or by any other regulator worldwide. Eli Lilly describes it as an investigational molecule, legally available only to people enrolled in its own clinical trials. Australian Research Peptides supplies it as a laboratory research chemical, not as a medicine, and not for use in people or animals. Check your own obligations before handling it.
Retatrutide holds no approval from the US Food and Drug Administration, nor from any other medicines regulator anywhere. Eli Lilly still describes it as an investigational molecule. Its phase 3 obesity programme, TRIUMPH-1, reported 80-week topline results in 2,339 adults during 2026, which marks progress toward a submission rather than a licence. Research-grade powder sits a further step removed, assessed by no one at all.
Retatrutide is banned for any tested athlete. Still in Phase 3 trials with no approval from a government health regulator, it falls inside category S0 — the sweep capturing investigational molecules — and that ban runs year-round, not merely on competition day. Australian competitors are governed by Sport Integrity Australia, where a positive sample counts whatever the athlete intended.
Retatrutide cannot be bought from an Australian pharmacy. No regulator anywhere has approved it, so no pharmacist can dispense it on prescription and no compounding pharmacy can lawfully make it up. There is no approved pen or pre-filled device version of it in this country. What Australian Research Peptides supplies is the research compound, a dry powder in a glass vial.